Early Initiation of Lopinavir/Ritonavir in Infants Less Than 6 Weeks of Age: Pharmacokinetics and 24 Week Safety and Efficacy

Ítems similars

• Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir/ritonavir combination antiretroviral therapy
  per: Chadwick, Ellen G., et al.
  Publicat: (2011)
• Assessment of Lopinavir Pharmacokinetics With Respect to Developmental Changes in Infants and the Impact on Weight Band–Based Dosing
  per: Nikanjam, Mina, et al.
  Publicat: (2011)
• Pharmacokinetics of High-Dose Lopinavir-Ritonavir with and without Saquinavir or Nonnucleoside Reverse Transcriptase Inhibitors in Human Immunodeficiency Virus-Infected Pediatric and Adolescent Patients Previously Treated with Protease Inhibitors
  per: Robbins, Brian L., et al.
  Publicat: (2008)
• Dynamics of the resting CD4(+) T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age
  per: Persaud, Deborah, et al.
  Publicat: (2012)
• Pharmacokinetics of Lopinavir/Ritonavir Crushed versus Whole Tablets in Children
  per: Best, Brookie M., et al.
  Publicat: (2011)